Literature DB >> 11396967

A transgenic mouse expressing human CYP4B1 in the liver.

S Imaoka1, K Hayashi, T Hiroi, Y Yabusaki, T Kamataki, Y Funae.   

Abstract

The human CYP4B1 protein was expressed in the liver of a transgenic mouse line under the control of the promoter of the human apolipoprotein E (apo E) gene. Hepatic microsomes of transgenic mice catalyzed omega-hydroxylation of lauric acid and also activated 2-aminofluorene (2-AF), which is a typical substrate for CYP4B1, to mutagenic compounds detected by an umu gene expression assay. These activities observed in transgenic mouse were efficiently inhibited by CYP4B1 antibody. However, such inhibition was not observed in control mice. This is the first report to indicate catalytic activities of human CYP4B1. For further characterization of human CYP4B1, a fusion protein of CYP4B1 and NADPH-P450 reductase was expressed in yeast cells. It was able to activate 2-AF and was also able to catalyze omega-hydroxylation of lauric acid. This transgenic mouse line and the recombinant fusion protein provide a useful tool to study human CYP4B1 and its relation to chemical toxicity and carcinogenesis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396967     DOI: 10.1006/bbrc.2001.5055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  Ligand characterization of CYP4B1 isoforms modified for high-level expression in Escherichia coli and HepG2 cells.

Authors:  Katharina Roellecke; Vera D Jäger; Veselin H Gyurov; John P Kowalski; Stephanie Mielke; Allan E Rettie; Helmut Hanenberg; Constanze Wiek; Marco Girhard
Journal:  Protein Eng Des Sel       Date:  2017-03-01       Impact factor: 1.650

Review 3.  P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Authors:  Karl-Dimiter Bissig; Weiguo Han; Mercedes Barzi; Nataliia Kovalchuk; Liang Ding; Xiaoyu Fan; Francis P Pankowicz; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

Review 4.  Cytochrome P450 and xenobiotic receptor humanized mice.

Authors:  Frank J Gonzalez; Ai-Ming Yu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

5.  Near completely humanized liver in mice shows human-type metabolic responses to drugs.

Authors:  Chise Tateno; Yasumi Yoshizane; Naomi Saito; Miho Kataoka; Rie Utoh; Chihiro Yamasaki; Asato Tachibana; Yoshinori Soeno; Kinji Asahina; Hiroshi Hino; Toshimasa Asahara; Tsuyoshi Yokoi; Toshinori Furukawa; Katsutoshi Yoshizato
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

6.  Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol.

Authors:  Constanze Wiek; Eva M Schmidt; Katharina Roellecke; Marcel Freund; Mariko Nakano; Edward J Kelly; Wolfgang Kaisers; Vladimir Yarov-Yarovoy; Christof M Kramm; Allan E Rettie; Helmut Hanenberg
Journal:  Biochem J       Date:  2015-01-01       Impact factor: 3.857

7.  Comparing the effects of an exposure to a polycyclic aromatic hydrocarbon mixture versus individual polycyclic aromatic hydrocarbons during monocyte to macrophage differentiation: Mixture exposure results in altered immune metrics.

Authors:  Brian C Tooker; Kevin Quinn; Michael Armstrong; Alison K Bauer; Nichole Reisdorph
Journal:  J Appl Toxicol       Date:  2021-02-08       Impact factor: 3.628

8.  Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidae during Evolution.

Authors:  Eva M Schmidt; Constanze Wiek; Oliver T Parkinson; Katharina Roellecke; Marcel Freund; Michael Gombert; Nadine Lottmann; Charles A Steward; Christof M Kramm; Vladimir Yarov-Yarovoy; Allan E Rettie; Helmut Hanenberg
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.